Are there specific forms for yervoy financial assistance?

Eligibility for Yervoy Financial Assistance

Patients may be eligible for financial assistance programs to help cover the cost of Yervoy (ipilimumab), a cancer medication used to treat advanced melanoma. According to the Bristol-Myers Squibb patient portal, the manufacturer of Yervoy [1], various financial assistance programs are available for patients who meet specific eligibility criteria.

Programs for Yervoy Financial Assistance

1. Bristol-Myers Squibb Patient Assistance Program: This program provides free or reduced-cost medication to eligible patients who have no insurance or are underinsured. Patients can apply through the company's website or by phone [1].
2. Patient Access Network (PAN): PAN offers financial assistance to patients with insurance coverage, but who are still facing high out-of-pocket costs. Eligible patients can apply through the PAN website [2].
3. Cancer Care Co-Payment Assistance Program (CCC) of Merck: This program provides copayment assistance to eligible patients prescribed Yervoy. Patients can apply through the CCC website or by phone [3].

Additional Assistance Options

Patients may also be eligible for government programs, such as Medicare Part D or Medicaid, which can help cover the cost of Yervoy. Additionally, some pharmacies offer programs to help reduce the cost of prescription medications, including Yervoy.

Application Process

To apply for financial assistance programs, patients can visit the respective websites or contact the organizations directly. Patients should provide required documentation, such as proof of income and insurance information, to support their application.

References

[1] Bristol-Myers Squibb. (n.d.). Patient Assistance Program. Retrieved from https://www.bms.com/our-company/patient-assistance-program/index.jsp

[2] PAN Foundation. (n.d.). Patient Access Network (PAN) Foundation. Retrieved from https://www.panfoundation.org/

[3] CCC of Merck. (n.d.). Cancer Care Co-Payment Assistance Program (CCC) of Merck. Retrieved from https://www.cccmerck.com/

Dr.ugs Patented

Yervoy (ipilimumab) patent expiry in the United States is in 2027, however, it can vary in other countries.

Clinical trial Data

More information on clinical trial data for Yervoy can be obtained from Clinicaltrials.gov [4]

[4] ClinicalTrials.gov. (n.d.). Search Results. Retrieved from https://clinicaltrials.gov/